A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral
- PMID: 35996427
- PMCID: PMC9392458
- DOI: 10.2147/JAA.S362588
A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral
Abstract
Asthma afflicts an estimated 339 million people globally and is associated with ill health, disability, and early death. Strong risk factors for developing asthma are genetic predisposition and environmental exposure to inhaled substances that may provoke allergic reactions. Asthma guidelines recommend identifying causal or trigger allergens with specific IgE (sIgE) testing after a diagnosis of asthma has been made. Allergy testing with sIgE targets subpopulations of patients considered at high risk, such as those with frequent exacerbations, emergency visits or hospitalizations, or uncontrolled symptoms. Specific recommendations apply to preschool children, school-age children, patients with persistent or difficult-to-control asthma, patients needing oral corticosteroids or high-dose inhaled steroids, patients seeking understanding and guidance about their disease, and candidates for advanced therapies (biologics, allergen immunotherapy). Allergen skin testing is common in specialized settings but less available in primary care. Blood tests for total and sIgE are accessible and yield quantifiable results for tested allergens, useful for detecting sensitization. Results are interpreted in the context of the patient's clinical presentation, age, and relevant allergen exposures. Incorporating sIgE testing into asthma management adds objective information to identify specific allergies and can guide personalized treatment plans, which reinforce patient-doctor communication. Test results can also be used to predict exacerbations and response to therapies. Additional diagnostic information can be gleaned from (i) eosinophil count ≥300 μL, which significantly increases the odds of having exacerbations, and emerging eosinophil biomarkers (eg, eosinophil-derived neurotoxin), which can be measured in plasma or serum samples, and (ii) fractional exhaled nitric oxide (FeNO), with values ≥25 ppb regarded as the cutoff for diagnosis, evaluating inhaled corticosteroid response, and of probable response to anti-IgE, anti-IL4 and anti-IL5 receptor biologics. Referral to asthma/allergy specialists is warranted when the initial diagnosis is uncertain, and when asthma symptoms, impairment, or exacerbations are repeated or severe.
Keywords: allergy; asthma; component resolved diagnostics; primary care; sensitization; specific IgE.
© 2022 Demoly et al.
Conflict of interest statement
David Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Thermofisher; consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. Dr. Rodriguez del Rio reports personal fees from ALK Abello, grants and personal fees from Aimmune Therapeutics, grants from Merck, personal fees from GSK, personal fees from FAES, personal fees from Novartis, personal fees from Thermo Fisher, personal fees from LETI Pharma, personal fees from Allergy Therapeutics, personal fees from Miravo, outside the submitted work. Dr Liu reports consultant fees paid to his university employer from Thermo Fisher; Avillion and Labcorp; research grants paid to his university from ResMed Propeller Health, Revenio, and Avillion. Dr Casale reports consulting fees from Thermo Fisher Scientific, Genentech, Novartis, outside the submitted work. Dr. Pedersen reports personal fees from AstraZeneca, personal fees from ALK, personal fees from Thermo Fisher Scientific, outside the submitted work. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
Low-grade disease activity in early life precedes childhood asthma and allergy.Dan Med J. 2016 Aug;63(8):B5272. Dan Med J. 2016. PMID: 27477800 Review.
-
Allergic Asthma in the Era of Personalized Medicine.J Pers Med. 2022 Jul 18;12(7):1162. doi: 10.3390/jpm12071162. J Pers Med. 2022. PMID: 35887659 Free PMC article. Review.
-
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25. Lancet Respir Med. 2021. PMID: 34181876
-
Analysis of the immunoglobin E molecular sensitization profile in children with allergic asthma and predictive factors for the efficacy of allergy immunotherapy.Ann Transl Med. 2020 Nov;8(21):1459. doi: 10.21037/atm-20-7314. Ann Transl Med. 2020. PMID: 33313204 Free PMC article.
-
Blood Biomarkers of Sensitization and Asthma.Front Pediatr. 2019 Jun 19;7:251. doi: 10.3389/fped.2019.00251. eCollection 2019. Front Pediatr. 2019. PMID: 31275911 Free PMC article. Review.
Cited by
-
A novel test for type-I allergy based on crosslink formation of immunoglobulin-E receptors by allergen-specific immunoglobulin-E antibodies and an allergen.Sci Rep. 2023 Nov 11;13(1):19676. doi: 10.1038/s41598-023-46730-8. Sci Rep. 2023. PMID: 37951988 Free PMC article.
-
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729. Int J Mol Sci. 2025. PMID: 40004192 Free PMC article. Review.
-
Association of Metabolites, Nutrients, and Toxins in Maternal and Cord Serum with Asthma, IgE, SPT, FeNO, and Lung Function in Offspring.Metabolites. 2023 Jun 9;13(6):737. doi: 10.3390/metabo13060737. Metabolites. 2023. PMID: 37367895 Free PMC article.
References
-
- Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi:10.1016/S0140-6736(17)32154-2 - DOI - PMC - PubMed
-
- World Health Organization. Asthma. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed Dec 1, 2020.
-
- Liu A, Luskin A, Brown R, et al. The practical application of allergic trigger management to improve asthma outcomes: step 1: identify patients with allergic components of asthma. J Fam Pract. 2018;2018:S5–S13.
-
- The National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (NG80); November 29, 2017. Available from: https://www.nice.org.uk/guidance/ng80. Assessed Mar 13, 2020. - PubMed
Publication types
LinkOut - more resources
Full Text Sources